KURA Q4 2025 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-67.8% YoY

Gross Profit

$17M97.3% margin

Operating Income

-$86M-497.6% margin

Net Income

-$81M-467.2% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

-16.5%

Cash Flow

Operating Cash Flow

$117M

Free Cash Flow

$115M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$738M

Total Liabilities

$564M

Stockholders' Equity

$174M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$54M	-67.8%
Gross Profit	$17M	$54M	-68.7%
Operating Income	-$86M	-$22M	-284.2%
Net Income	-$81M	-$19M	-321.5%